National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 4) (No. PB 31 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L00438

 
PB 31 of 2014
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No. 4)
 
National Health Act 1953
___________________________________________________________________________
 
I, Kim Bessell, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
 
Dated   15 April 2014
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Principal Pharmacy Advisor                                                                     
Pharmaceutical Benefits Division
Department of Health
 
___________________________________________________________________
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2014 (No.4).
 
(2)                This Instrument may also be cited as PB 31 of 2014.
2             Commencement
                This Instrument commences on 1 May 2014.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
[1]     Schedule 1 Part 1, entry for Docetaxel in the form ‘Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent’ with manner of administration Injection:
omit:      
Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent
Injection
AS-Docetaxel
YA
MP
C3888 C3892 C3916 C3956
C4078
C4140
C4160
C4239
D

 
 
 
 
 
 
 

[2]     Schedule 1 Part 1, after the entry for Doxorubicin in the form ‘Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial’ with manner of administration Injection/intravesical and brand ‘Doxorubicin Ebewe’:
insert:    
Doxorubicin MYX
YN
MP
 
D
 
[3]     Schedule 3, Responsible Person codes, after entry for YA:
insert:
YN
Mayne Pharma International Pty Ltd
 88 007 870 984 
 
Read Entire Law on www.comlaw.gov.au